OBJECTIVE — To assess the performance of urinary total protein measurements in timed 24-h urine collection (24-h UP) and in a diurnal random urine specimen (RUS) for the screening and diagnosis of overt diabetic nephropathy.

RESEARCH DESIGN AND METHODS — A total of 167 diabetic patients (20 type 1 and 147 type 2 diabetic patients; 78 women and 89 men), aged 20–84 years, collected 217 timed 24-h urine specimens. Albumin was measured by immunoturbidimetry; total protein by sulfosalicylic acid technique, and creatinine by Jaffe’s method. According to the timed 24-h urinary albumin excretion rate (UAER), samples were divided into three groups: normoalbuminuric (NORMO) (UAER <20 µg/min; n = 84), microalbuminuric (MICRO) (UAER 20–200 µg/min; n = 78), and macroalbuminuric (MACRO) (UAER ≥200 µg/min; n = 55). Eighty-six patients also collected 105 RUSs (NORMO, n = 47; MICRO, n = 37; MACRO, n = 21), and urinary protein concentration (UPC) and urinary protein-to-creatinine ratio (UPCR) were measured. The receiver operating characteristics (ROC) curve approach was used to analyze the performance of the diagnostic tests.

RESULTS — Spearman’s coefficient of correlation of 24-h UAER versus 24-h UP was 0.95 (P < 0.001), and of 24-h UAER versus UPC and UPCR were 0.77 and 0.72, respectively (P < 0.001). The calculated areas (±SEM) under the ROC curve for the diagnosis of overt diabetic nephropathy were 0.998 ± 0.001 for 24-h UP, 0.992 ± 0.006 for UPC, and 0.975 ± 0.014 for UPCR. In the ROC curves, the first points with 100% specificity were 541 mg (95.7% specificity) for 24-h UP, 431 mg/1 (92.9% specificity) for UPC, and 0.2 (76.2% specificity) for UPCR.

CONCLUSIONS — Measurements of proteinuria presented almost perfect accuracy for the screening and diagnosis of overt diabetic nephropathy. Protein measurement in spot urine is a reliable and simple method for the screening and diagnosis of overt diabetic nephropathy.

The screening and diagnosis of diabetic nephropathy have been based on the measurement of urinary albumin excretion rate (UAER) in a timed 24-h or overnight urine collection or on albumin-to-creatinine ratio or albumin concentration in a random or early-morning urine sample (1–5). The measurement of urinary albumin by accurate methods (immunoturbidimetry or radioimmunoassay) is essential for the diagnosis of the microalbuminuric phase of diabetic nephropathy, or incipient nephropathy, which can be halted or even reversed if appropriate measures are taken (6). It was demonstrated that screening and intervention for microalbuminuria are worthwhile, can have life-saving effects, and lead to considerable economic savings (7). However, financial constraint in some diabetic clinics has been considered the main reason limiting the use of urinary albumin measurements to screen for diabetic nephropathy (8). Classically, the diagnosis of overt diabetic nephropathy is established when Albustix results are persistently positive or when total urinary protein (UP) excretion is >0.5 g/24 h (9). In a recently published position statement, the American Diabetes Association recommends that screening for diabetic nephropathy should start with a routine urinalysis for protein (10). A dipstick test is used by most laboratories and is considered to have high sensitivity. A positive test result ought to be confirmed by quantitative protein measurement. If the test result is negative, measurement of albuminuria is necessary. The measurement of proteinuria by biochemical methods is simple and inexpensive and could increase the accuracy of the dipstick test for the initial screening of diabetic nephropathy. There are few data comparing the dipstick test with measurements of total proteinuria and albuminuria for the diagnosis of overt diabetic nephropathy (11,12).

The aim of this study was to assess the performance of total UP measurements in timed 24-h urine collection and in a diurnal random urine sample (RUS) for the screening and diagnosis of overt diabetic nephropathy by using the receiver operating characteristics (ROC) curve approach.

RESEARCH DESIGN AND METHODS — We performed a study of diagnostic tests for overt diabetic nephropathy (macroalbuminuria). The criterion standard was timed 24-h UAER. The study was done at the outpatient diabetes clinic of the Hospital de Clinicas de Porto Alegre (a tertiary care center). Informed consent was obtained from each patient, and the protocol was approved by the ethics committee.

Every type 1 and type 2 diabetic patient (defined according to the World Health Organization’s criteria) without evidence of cardiac failure or renal tract disease other than diabetic nephropathy (urinary tract infection, hematuria, abnormal urinary sediment, plasma creatinine increase without proteinuria) was considered for the study.
The study population consisted of 167 ambulatory diabetic patients (20 type 1 and 147 type 2 diabetic patients; 78 women and 89 men), aged 56.9 ± 12.3 years (range, 20–84). Patients were instructed in the collection of timed 24-h urine for measurements of UAER and total protein and were told to return on the morning after the end of urine collection. No specific recommendation was made about fluid intake, physical exercise, or dietary protein intake. Women were not examined during menstruation. The patients collected 217 timed 24-h urine specimens, all confirmed to be sterile by culture. According to 24-h UAER (criterion standard), samples were divided into three groups: normoalbuminuric (NORMO) (UAER <20 μg/min; n = 84), microalbuminuric (MICRO) (UAER 20–200 μg/min; n = 78), and macroalbuminuric (MACRO) (UAER ≥200 μg/min; n = 55). During the morning visit to the clinic, after completing the timed 24-h urine collection and after the first voided urine sample (not necessarily the second voided urine sample), 86 patients also collected RUSs for measurements of urinary protein concentration (UPC) and urinary protein-to-creatinine ratio (UPCR) and for the dipstick test. Fasting was not a criterion for collecting the RUS sample. This procedure was performed twice by 19 patients on different occasions; then 105 urine samples were analyzed. According to the 24-h UAERs, these samples were also divided into NORMO (n = 47), MICRO (n = 37), and MACRO (n = 21) groups.

Urinary albumin was measured by immunoturbidimetry (Sera-Pak, Bayer, Tarrytown, NY) in duplicate. The mean intraand interassay coefficients of variation (CVs) were 4.5 and 11.0%, respectively, at our laboratory. Urinary total protein was measured by the quantitative 3% sulfosalicylic acid assay CVs of these samples were 1.6, 4.6, and 8.1%, respectively. The semiquantitative dipstick method for proteinuria (Combur M, Boehringer Mannheim, Mannheim, Germany) was performed according to the directions of the manufacturer. Urinary creatinine was measured by Jaffe’s reaction (CV = 7.2%) (CentrifiChem Auto-Analyser, Hoffman-La Roche, Basel, Switzerland).

The relationship between 24-h UAER and 24-h UP and RUS measurements (UPC and UPCR) was calculated by Spearman's correlation coefficient (rS). The contribution (%) of urinary albumin to total protein in timed 24-h urine was determined in NORMO, MICRO, and MACRO samples, and the contributions of urinary albumin to total protein were compared using the Kruskal-Wallis analysis of variance (ANOVA) and nonparametric multiple comparison test. Sensitivities and specificities of total protein measurements in timed 24-h urine and in RUSs (UPCs and UPCRs) as a diagnostic test for overt diabetic nephropathy were calculated in each sample. The ROC-curve approach was used to analyze the performance of the screening tests. The true-positive rate (sensitivity) versus the false-positive rate (100 — specificity) was plotted for each measurement. The first point with 100% sensitivity was chosen in each curve, and a second cutoff point was also determined in each curve by the intersection of the curves with the 100%-to-100% diagonal. The latter point represents the best equilibrium between sensitivity and specificity. The statistical analyses of ROC curves were done using a Visiscal software version 5.0, which calculates the area under the curves (15). In assessing the accuracy of the Combur M test for the diagnosis of overt diabetic nephropathy, the 24-h UAER was considered the criterion standard. The level of significance was set at 0.05.

RESULTS — The correlation of 24-h UAER to 24-h UP was 0.95 (n = 217, P < 0.001). When these urine samples were divided into the NORMO, MICRO, and MACRO groups, the values for rS were 0.61, 0.80, and 0.95, respectively (P < 0.001). The rS of 24-h UAER versus UPC and UPCR were 0.77 and 0.72, respectively (P < 0.001).

Table 1—Measurements of 24-h UAER, 24-h UP, and contribution of albumin to total protein in the 217 urine samples

| Sample group | n | 24-h UAER (μg/min) | 24-h UP (mg/24h) | Contribution of albumin to total protein (%) |
|--------------|---|------------------|-----------------|---------------------------------------------|
| NORMO        | 84 | 4.9 (0.1–19.5)   | 45.7 (6.5–323.7) | 16.8 (0.4–47.5) |
| MICRO        | 78 | 69.6 (20.3–197.8)| 230.9 (51.6–625.1)| 44.2 (14.3–76.9) |
| MACRO        | 55 | 627.7 (201.2–4,056.8) | 2,133.1 (541.2–12,123.5) | 47.1 (33.4–79.2) |

Data are medians (range) except for contributions of albumin to total protein, which are expressed as means (range).

When the performance of 24-h UP as a diagnostic test for microalbuminuria was analyzed, the calculated area under the ROC curve (±SEM) was 0.9665 ± 0.0106. In this curve, the first point with a sensitivity of 100% and the nearest point to the intersection of the curves with the 100%-to-100% diagonal. At these two cutoff points, the corresponding values of 24-h UAER were 201.2 and 321.1 μg/min, respectively, for 24-h UP. For the chosen UPC cutoff points, the corresponding 24-h UAER values were 307.1 μg/min (first point with a sensitivity of 100%) and 185.3 μg/min (intersection of 100%-to-100% diagonal), and for the UPCR cutoff points, they were 307.1 and 672 μg/min, respectively.

When the performance of 24-h UP as a diagnostic test for overt diabetic nephropathy was analyzed, the area under the ROC curve (±SEM) was 0.9987 ± 0.001. The calculated areas under the ROC curves for RUS and UPC (0.9926 ± 0.006) and UPCR (0.9751 ± 0.014) did not differ.

Table 2 presents the characteristics of the cutoff points for diagnosis of overt diabetic nephropathy according to the first point with a sensitivity of 100% and the nearest point to the intersection of the curves with the 100%-to-100% diagonal.

![Image](image-url)
Proteinuria for diagnosis of overt diabetic nephropathy

and spot urine samples, as analyzed by the area under the ROC curve, are accurate for the screening and diagnosis of overt diabetic nephropathy. The values of the estimated area under the curves were close to 1.0, which represents perfect accuracy. Interestingly, the 100%-sensitivity cutoff value of 541 mg in 24-h urine is very similar to the value of 500 mg/24 h, which was adopted to define overt diabetic nephropathy (9). Few studies have compared the measurements of total proteinuria and albuminuria for the diagnosis of diabetic nephropathy (11,12). These studies analyzed only patients with overt diabetic nephropathy (11) or were designed for the diagnosis of microalbuminuria (12) and did not use the ROC-curve approach. The ROC curve has been used to evaluate over-all test performance (14,15) and to compare the discriminating ability of clinical tests (16). As far as we know, no other study used this approach to analyze the performance of proteinuria for the diagnosis of overt diabetic nephropathy. For the screening of a disease, it is desirable to have a test that is highly sensitive and, if possible, highly specific (17). High sensitivity and specificity were found in the present study because the 100%-sensitivity cutoff values of total proteinuria in 24-h and random urine (UPC) were highly specific (95.7 and 92.9%, respectively). This was not observed when proteinuria was corrected for urine creatinine in spot urine (UPCR). The specificity was only 76.2% at the cutoff value with 100% sensitivity. This means that about 25% of patients diagnosed by this test as having overt diabetic nephropathy would go on to be wrongly diagnosed. These errors are probably due to an increase in tubular secretion of creatinine in patients with nephrotic syndrome (18) and the interference of ketone bodies and some drugs in the creatinine assay method (19).

Moreover, the creatinine measurement increases the cost of the screening test. The quantitative measurement of total protein in the same spot sample of urine that is positive on the semiquantitative dipstick test will increase the accuracy of routine urinalysis for the diagnosis of overt diabetic nephropathy. Furthermore, the measurement of total protein in a RUS could be used to follow patients with overt diabetic nephropathy at a lower cost than the measurement of albuminuria. At our institution, the cost per test is as follows (all amounts expressed in U.S. currency): dipstick method, $0.61; protein measurement by sulfosalicylic method, $0.17; automated immunoturbidimetry for albumin, $0.78. These economic data took into account the cost of the materials used (Combur M, $0.51 per strip; sulfosalicylic method, $0.001; automated immunoturbidimetry for albumin; $0.77), the time expended to perform each test (1.00, 1.68, 0.10 min, respectively), and the hourly rate of a technician ($6.00).

This study confirms that 24-h proteinuria is not suitable for the screening of microalbuminuria because the specificity of the first point with 100% sensitivity on the ROC curve was unacceptably low. Considering that the detection of microalbuminuria is important in forestalling the development of advanced renal disease (5), it is imperative that accurate methods be used to test dipstick negative urine samples for albuminuria.

The use of 24-h UP and UAER produced a positive and significant correlation over a wide range of values. This correlation was stronger in macroalbuminuric (0.95) and microalbuminuric (0.80) samples than in normoalbuminuric samples (0.61). A close correlation between albumin and total protein excretion was also observed by other authors in a small sample (n = 11) of type 1 diabetic patients with

Table 2—Characteristics of the cutoff points of 24-hour UP, UPC, and UPCR as diagnostic tests for overt diabetic nephropathy

|                  | 24-h UP (mg/24 h) | UPC (mg/l) | UPCR (mg/mg) |
|------------------|-------------------|------------|--------------|
| Cutoff point     | Cutoff 1          | Cutoff 2   | Cutoff 1     | Cutoff 2   |
|                  | 541               | 568        | 431          | 490        | 0.2         | 0.5         |
| Sensitivity (%)  | 100               | 98.2       | 100          | 95.2       | 100         | 90.5        |
| Specificity (%)  | 95.7              | 97.5       | 92.9         | 95.2       | 76.2        | 90.5        |
| Accuracy (%)     | 96.8              | 97.7       | 94.3         | 95.2       | 80.9        | 90.5        |

Cutoff 1 is the first cutoff point with 100% sensitivity; cutoff 2 is the nearest point to the intersection of the curve with the 100%-to-100% diagonal.
overt diabetic nephropathy (11). The weaker correlation in normoalbuminuric samples could be explained by a diminutive fraction of albumin in the total protein at those low levels of proteinuria. After the development of diabetic renal disease, there is a progressive increase in urinary albumin and total protein excretion. The mean contribution of albumin to total protein was approximately 45% in both micro- and macroalbuminuric samples, which was significantly different from the proportion found in the normoalbuminuric samples (17%). These results are similar to those previously reported by Viberti et al. (20), who observed that the contribution of albumin to total protein was respectively 7, 15, and 42% in the urine samples of control subjects (UAER range, 4–26.2 mg/24 h), patients with microproteinuria (UAER <150 mg/24 h; range, 18.7–122.8) and patients with macroproteinuria (UAER >150 mg/24 h; range, 157–6257). The different proportions observed in the microproteinuric group and our microalbuminuric group are probably due to the different criteria used to classify the patients. According to the current classification of stages of diabetic nephropathy (10), patients with UAER levels in the upper range of microalbuminuria were excluded, and normoalbuminuric patients were included, in the group classified as microproteinuric by Viberti et al. (20).

In conclusion, proteinuria demonstrated almost perfect accuracy for the screening and diagnosis of overt diabetic nephropathy. Protein measurement in spot urine is a reliable and simple method for the screening and diagnosis of overt diabetic nephropathy.

Acknowledgments — This study was supported by grants from Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Fundo de Incentivo à Pesquisa do Hospital de Clínicas de Porto Alegre, and Programa de Apoio a Núcleos de Excelência. T.Z. is the recipient of a scholarship from Coordenacão de Aperfeiçoamento de Pessoal de Ensino Superior.

Part of this study was presented as an abstract at the International Diabetes Federation Meeting, Helsinki, Finland, 21–24 July 1997.

References

1. International Diabetes Federation, St. Vincent Declaration, World Health Organization. Consensus Guidelines for the Management of Insulin-Dependent Type 1 Diabetes. European IDDM Police Group, Eds. Bussum, The Netherlands, Medicom Europe, 1993

2. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 25:107–112, 1995

3. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, Froiland A, Hansen KW, Nielsen S, Pedersen MM: Microalbuminuria and the potential confounders: a review and some observations on variability of urinary albumin excretion. Diabetes Care 18:572–581, 1995

4. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of type 1 diabetes on the prevalence of diabetes mellitus defined by urinary albumin creatinine ratio. J Am Soc Nephrol 7:1–8, 1996

5. Zelmanovitz T, Gross JL, Oliveira JR, Paggi AF, Taisch M, Azevedo MJ: The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 20:516–519, 1997

6. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080–1084, 1995

7. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE: Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 306:1722–1725, 1993

8. Gazis A, Page SR: Microalbuminuria screening in the UK: are we meeting European standards? Diabet Med 13:764–767, 1996

9. Ireland JT, Viberti GC, Watkins PJ: The kidney and urinary tract. In Complications of Diabetes. 2nd ed. Keen H, Jarret J, Eds. London, Edward Arnold, 1982, p. 137–178

10. American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care 21(Suppl. 1):S50–S53, 1998

11. Sasse EA, Dounas BT, Lemann J Jr. Diabetic nephropathy: urinary albumin or total protein? Ann Intern Med 111:343–344, 1989

12. Phillipou G, James SK, Seaborn CJ, Phillips PJ: Screening for microalbuminuria by use of a rapid, low-cost colorimetric assay. Clin Chem 35:456–458, 1989

13. Bradley M, Schumann GB, Ward PCJ: Examination of urine. In Clinical Diagnosis and Management by Laboratory Methods. 16th ed. Henry JB, Ed. Philadelphia, WB Saunders, 1979, p. 559–634

14. Centor RM: A Visicalc program for estimating the area under a receiver operating characteristic (ROC) curve. Med Decis Making 5:139–148, 1985

15. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 149:29–36, 1983

16. Carrié BJ, McNeil BJ: A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology 148:839–843, 1983

17. Fletcher RH, Fletcher SW, Wagner EH: Diagnosis In Clinical Epidemiology: The Essentials. 3rd ed. Baltimore, MD, Williams & Wilkins, 1996, p. 43–74

18. Carrie BJ, Golbetz HV, Michaels AS, Myers BD: Creatinine: an inadequate filtration marker in glomerular diseases. Am J Med 69:177–182, 1980

19. Payne RB: Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 23:243–250, 1986

20. Viberti GC, Mackinson D, Keen H: Determinants of the penetration of proteins through the glomerular barrier in insulin-dependent diabetes mellitus. Diabetes 32(Suppl. 2):92–95, 1983